Evolución y repercusión científica de las becas de investigación de la Sociedad Española de Cardiología y la Fundación Española del Corazón (2000-2006) / Evolution and scientific impact of research grants from the spanish Society of Cardiology and Spanish Heart Foundation (2000-2006)

Introducción y objetivos. La Sociedad Española de Cardiología convoca anualmente becas para financiar proyectos de investigación en el campo de las enfermedades cardiovasculares. Nuestro objetivo es identificar la repercusión de estas inversiones durante el periodo 2000-2006 a partir de los artículos derivados de las becas y publicados en revistas científicas. Métodos. Utilizando los datos de identificación de cada proyecto como términos de búsqueda, se recuperaron todos los artículos derivados de estas becas en las bases de datos del Índice Médico Español, el Índice Bibliográfico Español en Ciencias de la Salud, el Science Citation Index-Expanded y Scopus. Los artículos se sometieron a un análisis estadístico descriptivo en relación con la tipología de las becas, la evolución anual de su número y de su importe, el sexo y las instituciones de los becados. Resultados. Se concedieron 207 becas con un importe total de 3.270.877 € y una dotación media anual de 467.268 €. De ellas, 123 (59,42%) aportaron publicaciones derivadas. El promedio de artículos publicados por beca concedida ha sido de 1,12, y de 1,9 si se tiene en cuenta únicamente las becas que dieron lugar a publicaciones. Conclusiones. Durante el periodo 2000-2006, la Sociedad Española de Cardiología/Fundación Española del Corazón destinó casi 500.000 € anuales a financiar becas de investigación y así contribuir a luchar contra las enfermedades cardiovasculares. Casi el 60% de las becas han aportado publicaciones derivadas, 231 artículos. El 73% de los artículos se publicaron en revistas extranjeras y el 91,34%, en revistas españolas o extranjeras con factor de impacto en el Journal Citation Report (AU)

Introduction and objectives. The Sociedad Española de Cardiología (Spanish Society of Cardiology) every year awards grants to finance research in the field of cardiovascular diseases. The aim of this study is to identify the impact of these investments during the period 2000-2006 from the subsequently published articles in scientific journals. Methods. Using the identifying data of each project as search terms, all articles that resulted from these grants were located in the Spanish Índice Médico Español and Índice Bibliográfico Español en Ciencias de la Salud databases, and in Science Citation Index-Expanded and Scopus. Descriptive statistical analysis of these articles included type of grant, number and amount awarded per year, and the recipient's sex and institutional affiliation. Results. The Sociedad Española de Cardiología awarded €3 270 877 to 207 recipients, an average annual total of €467 268, We identified 231 publications that resulted from 123 (59.42%) of these grants. The average number of articles per grant awarded was 1.12, and 1.9 when taking into account only the awards that led to publication. Conclusions. During the period 2000 to 2006, the Sociedad Española de Cardiología/ Fundación Española del Corazón (Spanish Heart Foundation) provided about €500 000 per year to fund research grants, thereby contributing to the fight against cardiovascular diseases. Almost 60% of grants have led to publications, 73% of which were published in international journals, and 91.34% in national or international journals with an impact factor in the Journal Citation Reports (AU)

[Evolution and scientific impact of research grants from the spanish society of cardiology and spanish heart foundation (2000-2006)]. / Evolución y repercusión científica de las becas de investigación de la Sociedad Española de Cardiología y la Fundación Española del Corazón (2000-2006).

INTRODUCTION AND OBJECTIVES: The Sociedad Española de Cardiología (Spanish Society of Cardiology) every year awards grants to finance research in the field of cardiovascular diseases. The aim of this study is to identify the impact of these investments during the period 2000-2006 from the subsequently published articles in scientific journals. METHODS: Using the identifying data of each project as search terms, all articles that resulted from these grants were located in the Spanish Índice Médico Español and Índice Bibliográfico Español en Ciencias de la Salud databases, and in Science Citation Index-Expanded and Scopus. Descriptive statistical analysis of these articles included type of grant, number and amount awarded per year, and the recipient's sex and institutional affiliation. RESULTS: The Sociedad Española de Cardiología awarded €3,270,877 to 207 recipients, an average annual total of €467,268. We identified 231 publications that resulted from 123 (59.42%) of these grants. The average number of articles per grant awarded was 1.12, and 1.9 when taking into account only the awards that led to publication. CONCLUSIONS: During the period 2000 to 2006, the Sociedad Española de Cardiología/ Fundación Española del Corazón (Spanish Heart Foundation) provided about €500,000 per year to fund research grants, thereby contributing to the fight against cardiovascular diseases. Almost 60% of grants have led to publications, 73% of which were published in international journals, and 91.34% in national or international journals with an impact factor in the Journal Citation Reports.

Cardiovascular scientific production in Spain and in the European and global context (2003-2007).

INTRODUCTION AND OBJECTIVES: The publication of research articles has increased considerably in recent years in all biomedical fields. The present study examines the position of Spanish quality research in cardiology in the European and world context, and its evolution during the 5-year period 2003-2007. METHODS: Using the Science Citation Index Expanded of Thomson Reuters as data source, we compared Spanish cardiovascular scientific production with that of the rest of countries in the European Union and of the most important countries worldwide, along with relative productivity as per number of inhabitants and Gross Domestic Product, and the number of citations in the journals of the <> area of the Journal Citation Reports (CCS-JCR). RESULTS: Spain ranks sixth in the European Union and ninth worldwide in scientific production (tenth worldwide if only the journals of the first quartile of the CCS-JCR area are considered). As regards the number of citations received, Spain ranks seventh in the European Union and eleventh worldwide. In terms of relative productivity as per number of inhabitants and Gross Domestic Product, the Spanish ranking is less favorable (positions 15 and 18, respectively). CONCLUSIONS: The ranking of Spanish cardiovascular research is similar to that of other biomedical fields, though its position is less favorable in relation to certain demographic and economical indicators. In order to maintain adequate investigational levels, it is necessary for the European governments and scientific societies to regard the promotion of high-quality cardiological research as a priority concern.

La producción científica cardiovascular en España y en el contexto europeo y mundial (2003-2007) / Cardiovascular Scientific Production in Spain and in the European and Global Context (2003-2007)

Introducción y objetivos. La publicación de artículos de investigación ha aumentado de manera considerable en los últimos años en todas las áreas biomédicas. El objetivo de este trabajo es determinar el lugar que ocupa la investigación cardiológica española de calidad en el contexto europeo y mundial y su evolución durante el quinquenio 2003-2007. Métodos. Utilizando como fuente de datos la base de datos Science Citation Index Expanded de Thomson Reuters, se comparó la producción científica cardiovascular española con la de los países de la Unión Europea y los más destacados del mundo, así como la productividad relativa respecto al número de habitantes y producto interior bruto y el número de citas recibidas en las revistas del área «Cardiac & Cardiovascular Systems» del Journal Citation Reports (CCS-JCR). Resultados. España ocupa el sexto puesto en el ranking europeo y el noveno en el mundial de la producción científica, pasando al décimo mundial si se consideran únicamente las revistas del primer cuartil del área CCS-JCR. En número de citas recibidas, España ocupa el séptimo lugar europeo y undécimo mundial. En la productividad relativa respecto al número de habitantes y el producto interior bruto, la posición española es menos favorable, ocupando la decimoquinta y la decimoctava posición, respectivamente. Conclusiones. En investigación cardiovascular, España ocupa posiciones similares a otras áreas biomédicas, si bien su situación es menos ventajosa respecto a algunos indicadores demográficos y económicos. Para que se mantengan los niveles adecuados de investigación, es necesario que los gobiernos y las sociedades científicas europeas consideren el fomento de la investigación cardiológica de alta calidad como un objetivo primordial (AU)

Introduction and objectives. The publication of research articles has increased considerably in recent years in all biomedical fields. The present study examines the position of Spanish quality research in cardiology in the European and world context, and its evolution during the 5-year period 2003-2007. Methods. Using the Science Citation Index Expanded of Thomson Reuters as data source, we compared Spanish cardiovascular scientific production with that of the rest of countries in the European Union and of the most important countries worldwide, along with relative productivity as per number of inhabitants and Gross Domestic Product, and the number of citations in the journals of the «Cardiac & Cardiovascular Systems» area of the Journal Citation Reports (CCS-JCR). Results. Spain ranks sixth in the European Union and ninth worldwide in scientific production (tenth worldwide if only the journals of the first quartile of the CCS-JCR area are considered). As regards the number of citations received, Spain ranks seventh in the European Union and eleventh worldwide. In terms of relative productivity as per number of inhabitants and Gross Domestic Product, the Spanish ranking is less favorable (positions 15 and 18, respectively). Conclusions. The ranking of Spanish cardiovascular research is similar to that of other biomedical fields, though its position is less favorable in relation to certain demographic and economical indicators. In order to maintain adequate investigational levels, it is necessary for the European governments and scientific societies to regard the promotion of high-quality cardiological research as a priority concern (AU)

[Erectile dysfunction as a marker of silent cardiovascular disease in type-2 diabetic patients in Spain. The DIVA (DIabetes and VAscular disease) study]. / Disfunción eréctil como marcador de vasculopatía en la diabetes mellitus tipo 2 en España. Estudio DIVA.

BACKGROUND AND OBJECTIVES: Erectile dysfunction (ED) is a sign of vascular disease in type 2 diabetic patients. The present subanalysis of the DIVA Registry, whose main objective was to estimate the prevalence of clinical vascular disorder and silent vascular disorder, as well as risk factors in type 2 diabetic patients treated in Spain, aims to analyze the relationship between those data and the prevalence of ED in these patients. PATIENTS AND METHODS: A total of 2444 type 2 diabetic patients (56% male; mean age 65.2 years) attended by 387 cardiologists and endocrinologists at ambulatory care were included. RESULTS: Coronary heart disease was present in 37% of the patients, cerebrovascular disease in 12%, and peripheral arterial disease in 13%. Forty percent of male patients had ED (according to the IIEF criteria), although in this group, as compared to those patients without ED, the prevalence of cardiovascular disease and signs of subclinical vascular disorder (microalbuminuria and abnormal ankle/brachial index (ABI)) was higher. The only independent predictor of ED was left ventricular hypertrophy (OR 5.2; 95% CI: 1.1-24.1; P=.03), with the ABI <0,9 being of borderline significance (OR 5.9; 95% CI: 0.9-39.9; P=.06). Poor glycemic and lipemic control (P<.05 in both cases) as well as cerebrovascular and peripheral arterial disease (P<.01 in both cases) and renal dysfunction (P<.001) were all more frequent among patients with severe ED. CONCLUSIONS: Forty percent of diabetic patients suffer from ED. The results of this study suggest that ED may be considered as an atherosclerosis marker and could be included in algorithms for risk stratification and subclinical vascular disorder detection.

Disfunción eréctil como marcador de vasculopatía en la diabetes mellitus tipo 2 en España. Estudio DIVA / Erectile dysfunction as a marker of silent cardiovascular disease in type-2 diabetic patients in Spain. The DIVA (Diabetes and Vascular disease) study

Fundamento y objetivo: la disfunción eréctil (DE) es un signo de enfermedad vascular en los sujetos con diabetes mellitus tipo 2 (DM2). El objetivo principal del estudio DIVA (por las letras iniciales de diabetes y vasculopatía) fue estimar la prevalencia de vasculopatía clínica y asintomática, así como la prevalencia de factores de riesgo en los sujetos diabéticos atendidos por especialistas en España; en él se analizó la relación de los datos citados con la prevalencia de DE. Pacientes y método: registro transversal compuesto por 2.444 sujetos consecutivos (56% varones con una edad media de 65,2 años) diagnosticados de DM2, atendidos en consulta por 387 cardiólogos y endocrinólogos. Resultados: el 37% de los sujetos presentaba cardiopatía isquémica, el 12% presentaba enfermedad cerebrovascular (ECRV) y el 13% presentaba arteriopatía periférica. El 40% de los varones tenía DE (según criterios del Índice internacional de la función eréctil), aunque en comparación con los grupos que no presentaban DE, en este grupo la enfermedad cardiovascular era significativamente más prevalente, así como los signos de vasculopatía subclínica (albuminuria e índice tobillo-brazo [ITB] anormal). El único factor predictor de DE independiente de otras variables de confusión fue la hipertrofia ventricular izquierda (riesgo relativo [RR] de 5,2; intervalo de confianza [IC] del 95%: 1,1¿24,1; p=0,03); el ITB fue menor que 0,9 de significación limítrofe (RR de 5,9; IC de 95%: 0,9¿39,9; p=0,06). El mal control glucémico y lipídico (p<0,05 en ambos casos) así como la presencia de ECRV, de enfermedad arterial periférica (p<0,01 en ambos casos) y de disfunción renal (p<0,001) eran más prevalentes en sujetos con DE grave. Conclusiones: el 40% de los varones diabéticos presenta DE. Los resultados de este estudio demuestran que la DE puede considerarse como marcador de aterosclerosis e incluirse en los algoritmos de estratificación de riesgo y detección de vasculopatía asintomática (AU)

Background and objectives: Erectile dysfunction(ED) is a sign of vascular disease in type 2 diabetic patients. The presents ubanalys is of the DIVA Registry, whos emain objective wast o estimate the prevalence of clinical vascular disorder and silent vascular disorder, as well as risk factors in type2diabetic patients treated in Spain, aims to analyze the relationship between those data and the prevalence of ED in these patients. Patients and Methods: A total of 2444 type 2 diabetic patients (56%male; meanage 65.2 years) attended by 387 cardiologists and endocrinologists at ambulatory care were included. Results: Coronary heart disease was present in 37%of the patients, cerebrovascular disease in12%,and peripheral arterial disease in 13%. Forty percent of male patients had ED (according to the IIEF criteria),although in this group, as compared to those patients without ED, the prevalence of cardiovascular disease and signs of subclinical vascular disorder (microalbuminuria and abnormalankle/brachialindex (ABI)) was higher. The only independent predictor of ED was left ventricular hypertrophy (OR5.2;95%CI: 1.1–24.1; P ¼ .03), with the ABI o0,9 being of border line significance (OR5.9;95%CI:0.9–39.9;P ¼ .06).Poor glycemic and lipemic control (Po.05 in both cases)as well as cerebrovascular and peripheral arterial disease (Po.01inbothcases) and renaldys function (Po.001)were all more frequent among patients with severe ED. Conclusions: Forty percent of diabetic patients suffer from ED. The results of this study suggest that EDmay be considered as an at hero sclerosis marker and could be included in algorithms for risk stratification and subclinical vascular disorder detection (AU)